149 related articles for article (PubMed ID: 30702508)
21. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
23. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ugurel S; Loquai C; Kähler K; Hassel J; Berking C; Zimmer L; Haubitz I; Satzger I; Müller-Brenne T; Mikhaimer NC; Becker JC; Kilian KJ; Schadendorf D; Heinzerling L; Kaatz M; Utikal J; Göppner D; Pföhler C; Pflugfelder A; Mössner R; Gutzmer R;
Ann Oncol; 2015 Mar; 26(3):573-82. PubMed ID: 25524477
[TBL] [Abstract][Full Text] [Related]
24. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
25. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
26. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
27. The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age.
Koh YW; Jung SJ; Yoon DH; Suh C; Cha HJ; Go H; Kim JE; Kim CW; Huh J
Hematol Oncol; 2015 Sep; 33(3):133-40. PubMed ID: 25224646
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma.
Gu L; Ma X; Xie Y; Li H; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
Clin Genitourin Cancer; 2017 Jun; 15(3):e369-e377. PubMed ID: 28038932
[TBL] [Abstract][Full Text] [Related]
29. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors.
Cocorocchio E; Martinoli C; Gandini S; Pala L; Conforti F; Stucchi S; Mazzarol G; Ferrucci P
Clin Transl Oncol; 2020 Oct; 22(10):1818-1824. PubMed ID: 32108276
[TBL] [Abstract][Full Text] [Related]
30. [Impact of preoperative lymphocyte to monocyte ratio on the prognosis of the elderly patients with stage II(-III( gastric cancer].
Cong X; Li S; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1144-1148. PubMed ID: 27781252
[TBL] [Abstract][Full Text] [Related]
31. Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma.
Jiang R; Cai XY; Yang ZH; Yan Y; Zou X; Guo L; Sun R; Luo DH; Chen QY; Huang PY; Xiang YQ; Lu X; Wang L; Xia WX; Mai HQ; Chen MY
Chin J Cancer; 2015 Jun; 34(6):237-46. PubMed ID: 26067059
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma.
Hutterer GC; Sobolev N; Ehrlich GC; Gutschi T; Stojakovic T; Mannweiler S; Pummer K; Zigeuner R; Pichler M; Dalpiaz O
J Clin Pathol; 2015 May; 68(5):351-5. PubMed ID: 25661796
[TBL] [Abstract][Full Text] [Related]
35. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B; Martens A; Geukes Foppen MH; Gebhardt C; Hassel JC; Rozeman EA; Gesierich A; Gutzmer R; Kähler KC; Livingstone E; Diamantopoulos PT; Gogas H; Madonna G; Ascierto PA; Goldinger SM; Mangana J; Garbe C; Schadendorf D; Blank C; Weide B
Cancer Immunol Immunother; 2019 May; 68(5):765-772. PubMed ID: 30806748
[TBL] [Abstract][Full Text] [Related]
36. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe S; Kimura K; Toyokawa T; Amano R; Tanaka H; Muguruma K; Hirakawa K
World J Gastroenterol; 2015 Sep; 21(34):9966-73. PubMed ID: 26379401
[TBL] [Abstract][Full Text] [Related]
38. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
39. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
Failing JJ; Yan Y; Porrata LF; Markovic SN
Melanoma Res; 2017 Dec; 27(6):596-600. PubMed ID: 29016387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
